13/09/2017 22:27:41

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Related content
31 Mar - 
Veloxis Announces the Total Number of Shares and Voting..
28 Mar - 
Veloxis Announces the Publication of ASERTAA (A Study o..
22 Mar - 
Notice to Convene Annual General Meeting 2018
Related debate
18 May - 
Den må jeg have misset... Burde regnskabet såvel som ko..
18 May - 
At tyde ud fra kommentarer i.f.m. seneste regnskab, er ..
18 May - 
Jeg ser foreløbig også den manglende kursstigning som e..

Company Release no. 19/2017

   

To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 13 September 2017

   

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

 

Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief Scientific Officer.  In this role, Dr. Meier-Kriesche will oversee the Company’s regulatory and medical affairs departments.

Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation.  He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals.  Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011.   

Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb.  Dr. Meier-Kriesche has also worked for Astellas Pharma.    

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said “Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment.  Ulf’s background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community.”

Ulf Meier-Kriesche commented “I am thrilled to join Veloxis because of the wonderful opportunity we have together to bring new therapeutic options to transplant patients.”

 

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 May
VELO
Har lyttet til det nu. Ikke så meget nyt, men bider mærke i, at Envarsus bliver mere og mere en fast..
13
14 May
VELO
Nu begynder Veloxis at levere varen. Det er klart, at med en vækst 142% i omsætning i forhold til Q1..
13
14 May
VELO
Imponerende vækst.... Det lover godt kombineret med de kommende nyheder omkring partnerskaber og De ..
12
15 May
VELO
For lige at sætte markedsmulighederne for EnvarsusXR i perspektiv, kommer der hver måned ca. 3000 ny..
10
14 May
VELO
Væksten fra Q1 2016 til Q1 2017 var på 100%. Til sammenligning er væksten fra Q1 2017 til Q1 2018 på..
8
18 May
VELO
At tyde ud fra kommentarer i.f.m. seneste regnskab, er der i mine øjne ingen tvivl om, at selskabet ..
7
17 May
VELO
msn. Som jeg ser det lider Veloxis stadig under, at de har en tidligere ledelse som lovede guld og g..
6
14 May
VELO
Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Velox..
6
17 May
VELO
Jeg ser ingen grund til, ikke at være optimistisk - Meltdoseteknologien er stadigvæk andre produktio..
5
15 May
VELO
VELO skriver selv i deres viksomhedsoversigt 2017 de har patent på Meldoseteknologien til 2028 i USA..
5

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
A10 NETWORKS DEADLINE ALERT: Rosen Law Firm Reminds A10 Networks, Inc. Investors of Important May 21 Deadline in First File Class Action– ATEN
2
8th Continent joins the Bancor decentralised liquidity network
3
Lambert Catches Record-Breaking Limit to Take Lead after Day Three of FLW Tour at Kentucky Lake Presented by Costa Sunglasses
4
Larson Electronics LLC Releases 10 Million Candlepower Rechargeable Handheld LED Spotlight
5
TheRecover.com, Drug Detoxification For San Jose Residents

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 May 2018 12:57:00
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB4 - 2018-05-20 13:57:00 - 2018-05-20 12:57:00 - 1000 - Website: OKAY